Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings

Published 23/09/2022, 11:48
Updated 23/09/2022, 12:40
© Reuters.  Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings

© Reuters. Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings

  • Citius Pharmaceuticals Inc (NASDAQ: CTXR) collaborated with the University of Pittsburgh for I/ONTAK (denileukin diftitox or E7777) in combination with Merck & Company, Inc. (NYSE: MRK) Keytruda (pembrolizumab) for recurrent or metastatic solid tumors.
  • The investigator-initiated trial at UPMC is an open-label, Phase 1/1b study consisting of two parts.
  • Part I is a dose escalation study of four cohorts and is expected to enroll 18-30 patients.
  • Part 2 is a dose expansion study of approximately 40 patients to evaluate the safety and tolerability of the recommended combination dose of I/ONTAK and pembrolizumab.
  • Related: Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm.
  • The study will also investigate the alteration of the immune microenvironment within tumors and peripheral blood.
  • Secondary endpoints include the objective response (complete response plus partial response), progression-free survival, and overall survival.
  • University of Pittsburgh dose-ranging study is expected to begin in the fourth quarter of 2022.
  • Additionally, Citius is collaborating with an investigator-initiated study at the University of Minnesota (UMN).
  • This Phase 1 dose-finding study to evaluate I/ONTAK before Novartis AG's (NYSE: NVS) Kymriah (tisagenleucel) CAR-T therapy for diffuse large B-cell lymphoma (DLBCL) enrolled its first patient in May 2021.
  • Price Action: CTXR shares closed 6.84% higher at $1.25 during after-hours trading on Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.